CD4 and inflammatory bowel disease: This suggests that T‐bet, or the factors that drive its upregulation, may be a therapeutic target in IBD, as it is required for the generation of IgG+ B cells and CD4+ Th1 cells, both of which have pathogenic roles in IBD.